VENTAVIS Nebuliser solution (2019)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Ventavis 10 microgram/ml nebuliser solution. Ventavis 20 microgram/ml nebuliser solution.
Qualitative and quantitative composition
Ventavis 10 microgram/ml nebuliser solution 1 ml solution contains 10 microgram iloprost (as iloprost trometamol). Each ampoule with 1 ml solution contains 10 microgram iloprost. Each ampoule with 2 ml ...
Pharmaceutical form
Nebuliser solution. Ventavis 10 microgram/ml nebuliser solution: Clear, colourless solution. Ventavis 20 microgram/ml nebuliser solution: Clear, colourless to slightly yellowish solution.
Therapeutic indications
Treatment of adult patients with primary pulmonary hypertension, classified as NYHA functional class III, to improve exercise capacity and symptoms.
Posology and method of administration
Drug product Suitable inhalation device (nebuliser) to be used Ventavis 10 microgram/ml Breelib I-Neb AAD Venta-Neb Ventavis 20 microgram/ml Breelib I-Neb AAD Ventavis should only be initiated ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Conditions where the effects of Ventavis on platelets might increase the risk of haemorrhage (e.g. active peptic ...
Special warnings and precautions for use
The use of Ventavis is not recommended in patients with unstable pulmonary hypertension, with advanced right heart failure. In case of deterioration or worsening of right heart failure transfer to other ...
Interaction with other medicinal products and other forms of interaction
Iloprost may increase the effects of vasodilatators and antihypertensive agents and then favour the risk of hypotension (see section 4.4). Caution is recommended in case of co-administration of Ventavis ...
Fertility, pregnancy and lactation
Women of childbearing potential Women of childbearing potential should use effective contraceptive measures during treatment with Ventavis. Pregnancy Women with pulmonary hypertension (PH) should avoid ...
Effects on ability to drive and use machines
Ventavis has major influence on the ability to drive and use machines for patients experiencing hypotensive symptoms such as dizziness. Care should be exercised during initiation of therapy until any effects ...
Undesirable effects
Summary of the safety profile In addition to local effects resulting from administration of iloprost by inhalation such as cough, adverse reactions with iloprost are related to the pharmacological properties ...
Overdose
Symptoms Cases of overdose were reported. Symptoms of overdoses are mainly related to the vasodilatory effect of iloprost. Frequently observed symptoms following overdose are dizziness, headache, flushing, ...
Pharmacodynamic properties
Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitors excluding heparin ATC code: B01AC11 Iloprost, the active substance of Ventavis, is a synthetic prostacyclin analogue. The ...
Pharmacokinetic properties
Absorption When iloprost at the concentration of 10 microgram/ml is administered via inhalation in patients with pulmonary hypertension or healthy volunteers (iloprost dose at the mouthpiece: 5 microgram: ...
Preclinical safety data
Systemic toxicity In acute toxicity studies, single intravenous and oral doses of iloprost caused severe symptoms of intoxication or death (intravenous) at doses about two orders of magnitude above the ...
List of excipients
Trometamol Ethanol 96% Sodium chloride Hydrochloric acid (for pH adjustment) Water for injections
Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Shelf life
Ventavis 10 microgram/ml nebuliser solution: 4 years. Ventavis 20 microgram/ml nebuliser solution: 5 years.
Special precautions for storage
This medicinal product does not require any special storage conditions.
Nature and contents of container
Ventavis 10 microgram/ml nebuliser solution 1 ml ampoules, colourless, glass type I, containing 1 ml nebuliser solution, ring coded with two coloured rings (white yellow). 3 ml ampoules, colourless, glass ...
Special precautions for disposal and other handling
For each inhalation session the content of one opened ampoule of Ventavis has to be transferred completely into the medication chamber immediately before use. After each inhalation session, any solution ...
Marketing authorization holder
Bayer AG, 51368, Leverkusen, Germany
Marketing authorization number(s)
Ventavis 10 microgram/ml nebuliser solution: EU/1/03/255/001 EU/1/03/255/002 EU/1/03/255/003 EU/1/03/255/004 EU/1/03/255/005 EU/1/03/255/006 EU/1/03/255/007 EU/1/03/255/008 EU/1/03/255/011 EU/1/03/255/013 ...
Date of first authorization / renewal of the authorization
Date of first authorisation: 16 September 2003 Date of latest renewal: 26 August 2013
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: